Barely Significant
← all excerpts

Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.

Target Oncol · 2025 · PMC12454471 · PMID 40958065

3
hedged sentences
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
Similarly, Kaplan–Meier analysis showed a trend for earlier grade ≥ 3 corneal exam findings with higher belantamab mafodotin exposures, but stepwise Cox regression found no significant associations with time to these exam findings.

also in 53,322 other papers

a slight trendno p-value reported
There was a slight trend of decreasing probability as cys-mcMMAF exposures increased, but this did not meet significance criteria, nor did any covariate association.

also in 4,078 other papers

a small trendno p-value reported
While logistic regression showed patients with these events had slightly higher belantamab mafodotin exposures, and there was a small trend for decreasing probability of event with increasing cys-mcMMAF exposures, neither exposure metric was significant.

also in 722 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.